Business
NRx Pharmaceuticals Reports Third-Quarter 2021 Business Update and Financial Results
RADNOR, Pa., Nov. 16, 2021 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals (Nasdaq: NRXP) (NRx), a clinical-stage, biopharmaceutical company, today provided a
About this update from Nrx Pharmaceuticals, Inc.
[{"type":"text","content":"RADNOR, Pa., Nov. 16, 2021 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals (Nasdaq: NRXP) (NRx), a clinical-stage, biopharmaceutical company, today provided a business update and financial results for the quarter ended September 30, 2021. NRx will host a conference call Tuesday morning, November 16th, at 8:30 AM Eastern Time to discuss its business update and third-quarter financial results. Investors and the general public are invited to listen to a live audio webcast of the conference call, which may be accessed five minutes before the start of the call by dialing (877) 705-6003 (U.S.), (201) 493-6725 (International) Conference ID: 13724953, or through the webcast link NRx Pharmaceuticals Third Quarter Results Call. A replay will be available from the NRx Pharmaceuticals website following the call at www.nrxpharma.com. “In our second quarter as a public company, we have broadened our focus from safety and efficacy alone to establishing the manufacturing and scalability of the medicines in our pipeline. With the financial resources afforded by our investors, we have now established the operations required to commercialize our investigational medicines starting next year,” said Prof Jonathan Javitt, MD, MPH, Chairman and CEO of NRx Pharmaceuticals. “We look forward to restarting our NRX-101 psychiatry clinical trials and continuing to advance the research and development of ZYESAMI and the BriLife vaccine.” Business Highlights in Q3, 2021 Overall This quarter reflects NRx’s second quarter of operations as a public company. NRx now has three-phase 3 investigational products, each of which has the potential for approval in 2022 or early 2023 and each of which represents a first-in-class medicine or vaccine for an unmet medical need. Those products are: ZYESAMI® (aviptadil), an FDA Fast Track medicine for the treatment of Respiratory Failure in COVID-19, with application to other lethal diseases that affect the lung. ZYESAMI is the first medicine to specifically protect the alveolar type II cell that is essential for respiratory function.BriLife™, a novel live virus vaccine that shows promise against COVID-19 and particularly against new variants of the SARS-CoV-2 virus, including the Delta variant.NRX-101, an FDA Fast Track and Breakthrough Therapy-designated medicine to treat patients with suicidal bipolar depression, is the first NMDA-t...